Semax is a nootropic drug developed in Russia. Its primary function is to enhance cognitive processes such as memory, learning, and concentration. It is believed to work by increasing the levels of neurotrophic factors in the brain, particularly brain-derived neurotrophic factor (BDNF), which promotes the survival and growth of neurons. It also affects neurotransmitter systems, including serotonin, dopamine, and glutamate, which are crucial for mood, motivation, and cognitive function.
Semax is a synthetic peptide composed of seven amino acids with the sequence Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP), which acts in the brain through several key mechanisms: it increases the production of proteins that support the growth and survival of brain cells, regulates the balance of neurotransmitters, controls gene expression, and reduces inflammation – all by interacting with numerous different receptors on the surface of nerve cells. Amino acids are the building blocks from which all proteins in the body are constructed.
Semax was created by modifying a small, naturally occurring fragment of a hormone called adrenocorticotropic hormone (ACTH) – a hormone released by the body in response to stress – specifically the ACTH(4-10) fragment. Scientists attached a short chain of three amino acids (Pro-Gly-Pro) to it in order to increase the peptide's resistance to breakdown in the body and prolong its duration of action [1], [2]. Importantly, although Semax originates from a stress hormone, it does not behave like a hormone. It does not cause cortisol release or any hormonal side effects, whilst retaining – and even enhancing – the neuroprotective properties of the original fragment [3]. This unique profile has made Semax one of the most widely studied neuroprotective and cognitive-enhancing peptides, with documented use in stroke treatment and cognitive function support.
Does Semax cross the blood-brain barrier?
Semax effectively crosses the blood-brain barrier after intranasal administration, reaching detectable concentrations in brain tissue within minutes. The blood-brain barrier is a highly selective protective layer surrounding brain blood vessels, which controls which substances can pass from the blood into brain tissue – many drugs and compounds are unable to cross it.
In studies using a radioactively labelled version of Semax – which allows researchers to track exactly where it goes in the body – rats administered Semax intranasally at a dose of 50 micrograms per kilogram of body weight showed detectable concentrations of the peptide in brain tissue as early as 2 minutes after administration. Approximately 80% of the substance reaching the brain consisted of intact, original Semax molecules, rather than its breakdown products [4]. Such rapid delivery is likely made possible by the olfactory pathway – the neural network responsible for the sense of smell – which runs directly from the nasal cavity to the brain, completely bypassing the bloodstream.
Research has also shown that Semax has a half-life – the time it takes for half of the substance to break down – exceeding one hour in the presence of cell membrane material [5]. This is significantly longer than for many naturally occurring brain signalling peptides, confirming Semax's ability to remain active in the brain long enough to exert significant effects.
Semax acts on the following receptors:
Semax interacts with several different types of receptors in the brain – these are specialised proteins on cell surfaces, acting like locks: when the right molecule – the key – binds to a receptor, it triggers a specific reaction inside the cell.
Due to its structural similarity to the ACTH(4-10) fragment, Semax exhibits the ability to interact with melanocortin receptors – a family of receptors involved in various brain and body functions – but does so in a non-hormonal and selective manner, without eliciting a full hormonal response [3]. Specialised binding studies – in which scientists used radiolabelled molecules to track Semax's binding sites on cell surfaces – identified specific binding sites on the outer membrane of nerve cells in a brain region known as the basal forebrain. These sites were found to be calcium-dependent (requiring calcium ions to bind), reversible (Semax can detach from them), and saturable (the number of these sites is finite). The binding affinity (expressed as the dissociation constant, Kd) was approximately 2.4 nM – a value indicating a rather strong and specific binding – and the total number of binding sites (Bmax) was 33.5 fmol per milligram of protein [6]. These sites differ from the receptors targeted by classical hormones.
Interestingly, the same studies showed that two breakdown fragments of Semax – the five-amino-acid peptides HFPGP and EHFPG – exhibited the strongest ability to compete for the same binding sites among all Semax metabolic products. This means that even after the original Semax molecule breaks down, its fragments continue to actively interact with the same receptors, effectively prolonging its duration of action [7].
Semax is also a proposed ligand for the μ-opioid receptor – a receptor better known for its role in pain processing and the action of opioids – as suggested by computer simulations in which scientists modelled molecular interactions. Via this receptor, Semax is thought to regulate the USP18 protein and influence the stability of lysosomes – cellular compartments responsible for the breakdown and recycling of cellular waste [8]. Further binding studies have shown that Semax also affects the activity of acetylcholine receptors (involved in memory, attention and muscle control) and GABA receptors receptors (which generate calming, inhibitory signals in the brain) in a dose-dependent manner, acting on both high- and low-affinity GABA binding sites [9].
Direct measurements of the electrical activity of isolated brain cells showed that Semax, at a concentration of 1 micromolar, increased the electrical currents triggered by GABA – inhibitory signals – in cerebellar Purkinje cells by approximately 147%. At the same time, it reduced the currents activated by glycine – another type of inhibitory signal – in hippocampal pyramidal cells (nerve cells in the brain’s memory centre) to approximately 43–68% of their normal level [10]. Semax also demonstrated competitive interaction with metabotropic glutamate receptors – receptors involved in learning, memory and synaptic plasticity – with an IC50 (the concentration required to produce a 50% inhibitory effect) of approximately 33 micromoles [11].
Semax influences BDNF and neurotrophic signalling by increasing levels of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). These factors are crucial for neuroplasticity, neuroprotection, and the growth and survival of neurons. Semax also modulates signalling pathways downstream of these growth factors, which can lead to improved cognitive function and amelioration of neurological deficits.
Semax consistently and significantly increases the production of key neurotrophic factors – proteins that the brain produces to keep its cells healthy, support their growth, the formation of new connections, and their survival following injury. The two most important of these are brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF).
In studies on rat hippocampal tissue – the hippocampus is the part of the brain most closely associated with learning and memory formation – a single nasal dose of Semax at 50 micrograms per kilogram of body weight caused a peak 1.4-fold increase in BDNF protein levels (meaning BDNF increased to 1.4 times its normal amount). It also induced a 1.6-fold increase in TrkB activation – the receptor BDNF binds to, which is how BDNF delivers its effects inside the cell – and a 3-fold and 2-fold increase in the genetic instructions (mRNA) for BDNF and TrkB, respectively. mRNA is the molecular message cells use to produce proteins; higher mRNA levels indicate the cell is actively increasing production. These molecular changes were accompanied by a measurable improvement in conditioned avoidance learning – a standard behavioural test used to assess memory and learning ability in animals [12].
In cultures of glial cells – supporting cells of the brain that maintain the environment for neurons – taken from the basal forebrain of a rat, Semax induced an 8-fold increase in BDNF mRNA and a 5-fold increase in NGF mRNA within just 30 minutes of its administration. This is one of the fastest and most potent neurotrophin-stimulating effects ever recorded for a synthetic peptide [13]. These effects also varied by brain region and time: studies tracking the activity of BDNF and NGF genes at multiple time points after Semax administration showed significant changes in the hippocampus, frontal cortex, and retina, with an initial transient decrease in hippocampal expression at 20 minutes, followed by a significant increase at 90 minutes and sustained elevated levels in the frontal cortex within the early post-administration window [14].
Crucially, the mechanism of BDNF augmentation has also been confirmed in humans. In a clinical trial involving 110 patients recovering from ischaemic stroke – a type of stroke caused by a blocked blood vessel cutting off oxygen supply to part of the brain – administration of Semax significantly raised blood BDNF levels, irrespective of the timing of rehabilitation initiation, and these elevated levels were sustained throughout the study period. Patients with higher increases in BDNF also showed greater improvement in the Barthel Index – a standard clinical scoring system measuring a person's ability to perform daily activities independently – and a faster return of motor function [15]. This evidence from human studies directly supports the practical significance of the neurotrophic mechanism observed in animal studies.
How does Semax modulate neurotransmitter systems?
Semax affects the two most important neurotransmitter systems – serotonin and dopamine. However, instead of directly increasing or decreasing their levels, it acts more like a fine-tuning mechanism, regulating the activity of these systems. Neurotransmitters are chemical messengers that nerve cells release to communicate with each other across small gaps called synapses.
In the striatum – a region of the brain involved in motor coordination, reward processing and habit formation – administration of Semax to rats significantly increased tissue levels of a molecule called 5-hydroxyindoleacetic acid (5-HIAA), which is a by-product of serotonin breakdown. Higher levels of 5-HIAA indicate increased serotonergic activity. Specifically, tissue levels of 5-HIAA increased by approximately 25% two hours after administration, whilst levels of 5-HIAA measured in the fluid surrounding brain cells gradually rose to approximately 180% of the baseline value over 1–4 hours [16]. This suggests that Semax induces a gradual and sustained increase in serotonergic activity in the striatum.
Regarding dopamine – the neurotransmitter most associated with motivation, reward, and movement – Semax did not alter dopamine levels in brain tissue or in the fluid surrounding brain cells under normal resting conditions on its own. However, when administered with D-amphetamine (a stimulant drug that causes a large release of dopamine), Semax significantly amplified the dopamine-releasing effect of the drug, resulting in a considerably higher peak dopamine level in the fluid surrounding brain cells and a more pronounced increase in motor activity compared to amphetamine alone [16], [17]. This pattern – where Semax potentiates the dopaminergic system's response to stimulation without directly triggering dopamine release – suggests it enhances the system's sensitivity or readiness, rather than acting as a direct stimulant. This aligns with the observation that Semax does not exhibit addictive potential.
How does Semax work on the gene expression level?
Semax regulates gene expression in the brain in a way that directly counteracts damage caused by stroke and stress – it reduces the expression of inflammatory genes and restores the expression of genes responsible for proper communication between nerve cells. Every cell in the body contains genes – biological instructions that tell cells which proteins to produce and when – and gene expression refers to whether a particular gene is actively being read and used to produce its protein at a given time.
In a stroke model in rats – where a blood vessel supplying the brain was temporarily blocked to simulate the type of damage that occurs in humans during a stroke – RNA sequencing analysis (a technique that provides a comprehensive overview of which genes are active or inactive across the entire genome at any given time) identified 394 genes whose activity levels differed in Semax-treated versus untreated animals, 24 hours post-stroke. Specifically, Semax reduced the activity of inflammation-driving genes that had been inappropriately switched on by the stroke, while reactivating genes involved in normal brain cell communication that had been inappropriately switched off [18]. More detailed analysis confirmed that Semax significantly reduced the mRNA levels – and thus the production instructions – for several key pro-inflammatory proteins: IL-1α, IL-1β, IL-6, CCL3, and CXCL2. These are signalling proteins that, when produced in excess, drive damaging inflammation in injured brain tissue. Semax effectively reversed the stroke-induced increase in their production [19].
Even in healthy rats without brain injury, a single dose of Semax altered the activity of 258 genes in the frontal cortex – the region of the brain responsible for decision-making, attention, and complex thought – with most of the changes involving a reduction in the activity of genes associated with the immune system [20]. This indicates that the gene-regulating effects of Semax are not limited to states of injury or disease; they are present even under normal, healthy conditions.
Jak działa Semax poprzez mechanizm synaktonu?
Semax acts not only as a single, intact molecule – the term „synacton” describes the concept that Semax functions as part of a coordinated biological system, comprising both the original peptide and the biologically active fragments into which it breaks down within the body. When enzymes – proteins that break down other molecules – act on Semax in biological tissues, they gradually cleave it into smaller fragments, primarily the five-amino-acid fragment HFPGP, followed by the three-amino-acid fragment PGP [5]. Crucially, these fragments are not merely inert by-products. Each retains its own independent biological activity at overlapping but distinct receptor sites on brain cells [7], which means that the overall pharmacological effect of a single dose of Semax extends far beyond the point at which the original molecule has already been cleared from the system.
PGP fragment in particular demonstrated the ability to independently activate neurotrophic factors and their receptors after a stroke, stimulate the growth and proliferation of neuroglial cells (support and maintenance cells of the brain) and vascular endothelial progenitor cells (cells forming the inner lining of new blood vessels), and regulate the activity of the VEGF gene – a gene controlling the formation of new blood vessels, which is crucial for tissue repair after injury [21], [22]. These independent actions of PGP significantly contribute to the overall neuroprotective and regenerative effects associated with Semax as a whole.
Co Co Semax robi w organizmie poza mozgiem?
Semax has documented effects on several organ systems outside of the brain, although most research focuses on its central action. Available evidence indicates significant effects on the cardiovascular, gastrointestinal, hepatic, and immune systems.
Within the cardiovascular system – the heart and blood vessels – Semax has shown antithrombotic (reducing clot formation) and fibrinolytic (promoting the breakdown of existing clots) effects. Nasal administration enhanced the blood's natural antithrombotic properties and its fibrinolytic activity, and reduced the size of experimentally induced clots in animal models [23]. Under stress conditions, such as immobilisation stress, Semax also prevented the abnormal increase in blood clotting tendency that stress typically induces, and supported the natural anticoagulant system [24].
In the digestive system – the stomach and intestines – Semax protected the gastric mucosa against damage caused by ulcer-inducing factors, including alcohol and stress, with protective effects comparable to those of the PGP fragment alone. It also accelerated the healing of gastric ulcers induced experimentally by acetic acid [25]. At doses of 50 and 150 micrograms per kilogram of body weight, Semax prevented stress-induced disruption of the gut microbiota – the community of beneficial bacteria living in the colon – in chronically stressed rats, maintaining populations of essential bacteria that would otherwise have been significantly reduced by prolonged stress associated with immobilisation [26].
In the liver, Semax exerted dose-dependent protective effects on liver cells both under short-termand long-term stress conditions, helping to normalise protein synthesis and reducing abnormal increases in liver enzymes – blood markers indicating liver cell damage [27]. In the immune system, Semax acted as an effective immunomodulator – a substance that helps restore normal immune function – in animals subjected to social stress, helping to restore normal cellular immunity, antibody-mediated immunity and the activity of neutrophils – a type of white blood cell that attacks pathogens – in combating infection, all of which had been disrupted by stress [28].
How does Semax interact with the HPA axis?
Semax does not activate the HPA axis and does not stimulate cortisol secretion – instead, it acts in the opposite direction, dampening the brain's stress response output. The hypothalamic-pituitary-adrenal (HPA) axis is the body's central stress response system, acting like a chain of command: when the brain registers stress, the hypothalamus signals the pituitary gland (a small gland at the base of the brain), which in turn signals the adrenal glands (small glands located on top of the kidneys) to secrete cortisol – the main stress hormone.
Although Semax is structurally a derivative of ACTH – one of the key hormones in this stress signalling chain – it does not activate the HPA axis and does not stimulate the secretion of cortisol or corticosterone (the main stress hormone in rodents) [3]. In the chronic unpredictable stress model – an animal research protocol in which rats are exposed to a series of unpredictable stressors over time to simulate the effects of chronic stress – Semax reversed the adrenal enlargement that typically develops under conditions of chronic stress [9]. Adrenal enlargement is a widely recognised physical symptom of prolonged overactivity of the HPA axis, so its reversal indicates that Semax reduced the overall burden on the stress response system.
The stress-attenuating effect was further confirmed by measurements of c-Fos expression – a protein whose presence within a cell is used as a marker indicating its recent activation – in the paraventricular nucleus of the hypothalamus, a specific region of the hypothalamus that initiates the stress hormone cascade. Semax pretreatment reduced c-Fos expression in this region in stress-susceptible rats, indicating reduced activation of the hypothalamic stress response to emotional stressors [29]. Taken together, the available evidence suggests that the anti-stress mechanism of Semax involves the suppression of the initial stress signalling in the brain, rather than the direct inhibition of hormone production in the adrenal glands.
Disclaimer
This article is for educational and informational-scientific purposes only and should not be interpreted as medical advice, diagnosis, therapeutic recommendation, or a claim regarding the efficacy of Semax in treating any condition. Semax remains an investigational compound in most countries, including the United States and most European countries, and is not approved by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for the treatment of any medical condition. It is approved and used clinically in Russia and some Eastern European countries. Most of the evidence presented in this article is derived from preclinical animal studies and a limited number of human clinical trials, many of which originate from Russian-language scientific literature. Additional, well-designed clinical trials are necessary to more accurately establish the safety, efficacy, mechanisms of action, and long-term effects of Semax in humans.
References
[1] Ashmarin, I. P., Nezavibat'ko, V. N., Miasoedov, N. F., Kamenskii, A. A., Grivennikov, I. A., Ponomareva-Stepnaya, M. A., Andreeva, L. A., Kaplan, A. Ia., Koshelev, V. B., & Riasina, T. V. (1997). A nootropic adrenocorticotropin analogue 4-10-semax (15 years' experience in its design and study). Journal of Higher Nervous Activity named after I. P. Pavlov, 47(2), 420–430. PMID: 9173745
[2] Asmarin, I. P., Nezavibatko, V. N., Miasoedov, N. F., Kamenskii, A. A., Grivennikov, I. A., Ponomareva-Stepnaia, M. A., Andreeva, L. A., Kaplan, A. Ya., Koshelev, V. B., & Riasina, T. V. (2005). Natural and hybrid („chimeric”) stable regulatory glyproline peptides. Pathophysiology, 11(4), 179–185. https://doi.org/10.1016/j.pathophys.2004.10.001
Ponomareva-Stepnaia, M. A., Porunkevich, E. A., Skuin’sh, A. A., Nezavibat’ko, V. N., & Ashmarin, I. P. (1986). Hormonal activity of the ACTH(4-10) analog — a prolonged-action stimulant of learning. Bulletin of Experimental Biology and Medicine, 101(3), 267–268. PMID: 3006824
[4] Shevchenko, K. V., Nagaev, I. Yu., Alfeeva, L. Yu., Andreeva, L. A., Kamenskiĭ, A. A., Levitskaia, N. G., Shevchenko, V. P., Grivennikov, I. A., & Miasoedov, N. F. (2006). Kinetics of Semax penetration into the brain and blood of rats after its intranasal administration. Bioorganic Chemistry, 32(1), 64–70. https://doi.org/10.1134/s1068162006010055
[5] Dolotov, O. V., Zolotarev, Yu. A., Dorokhova, E. M., Andreeva, L. A., Alfeeva, L. Yu., Grivennikov, I. A., & Miasoedov, N. F. (2004). The binding of Semax, ACTH 4-10 heptapeptide, to plasma membranes of the rat forebrain basal nuclei and its biodegradation. Biochemical Chemistry, 30(3), 241–246. https://doi.org/10.1023/b:rubi.0000030127.46845.f0
[6] Vyunova, T. V., Andreeva, L. A., Shevchenko, K. V., & Myasoedov, N. F. (2017). Synacton and individual activity of synthetic and natural corticotropins. Journal of Molecular Recognition, 30(5). https://doi.org/10.1002/jmr.2597
[7] Vyunova, T. V., Andreeva, L. A., Shevchenko, K. V., Shevchenko, V. P., Bobrov, M. Yu., Bezuglov, V. V., & Myasoedov, N. F. (2014). Characteristic features of specific binding of pentapeptide HFPGP labelled at the C-terminal proline residue to rat forebrain plasma membranes. Proceedings of Biochemistry and Biophysics, 456(1), 101–103. https://doi.org/10.1134/S1607672914030077
[8] Liu, R., Chen, Y., Huang, H., Li, X., Lv, J., Jiang, L., Jiang, H., Wu, C., Chen, W., Xu, H., Zhu, Z., Cai, H., Xiao, J., Yin, L., & Ni, W. (2025). Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice. British Journal of Pharmacology, 182(22), 5489–5516. https://doi.org/10.1111/bph.70122
Vyunova, T. V., Andreeva, L. A., Shevchenko, K. V., Glazova, N. Yu., Sebentsova, E. A., Levitskaya, N. G., & Myasoedov, N. F. (2023). Synthetic corticotropins and the GABA-receptor system: direct and delayed effects. Chemical Biology & Drug Design, 101(6), 1393–1405. https://doi.org/10.1111/cbdd.14221
[10] Sharonova, I. N., Bukanova, Yu. V., Myasoedov, N. F., & Skrebitskii, V. G. (2018). Modulation of GABA- and glycine-activated ionic currents with Semax in isolated cerebral neurons. Bulletin of Experimental Biology and Medicine, 164(5), 612–616. https://doi.org/10.1007/s10517-018-4043-8
[11] Firstova, Yu. Yu., Vasil’eva, E. V., & Kovalev, G. I. (2011). Investigating the specific effects of nootropic drugs on glutamate receptors in the rat brain. Experimental and Clinical Pharmacology, 74(1), 6–10. PMID: 21476267
[12] Dolotov, O. V., Karpenko, E. A., Inozemtseva, L. S., Seredenina, T. S., Levitskaya, N. G., Rozyczka, J., Dubynina, E. V., Novosadova, E. V., Andreeva, L. A., Alfeeva, L. Yu., Kamensky, A. A., Grivennikov, I. A., Myasoedov, N. F., & Engele, J. (2006). Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research, 1117(1), 54–60. https://doi.org/10.1016/j.brainres.2006.07.108
Shadrina, M. I., Dolotov, O. V., Grivennikov, I. A., Slominsky, P. A., Andreeva, L. A., Inozemtseva, L. S., Limborska, S. A., & Myasoedov, N. F. (2001). Rapid induction of neurotrophin mRNAs in rat glial cell cultures by Semax, an adrenocorticotropic hormone analogue. Neuroscience Letters, 308(2), 115–118. https://doi.org/10.1016/s0304-3940(01)01994-2
[14] Shadrina, M., Kolomin, T., Agapova, T., Agniullin, Y., Shram, S., Slominsky, P., Lymborska, S., & Myasoedov, N. (2010). Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action. Journal of Molecular Neuroscience, 41(1), 30–35. https://doi.org/10.1007/s12031-009-9270-z
[15] Gusev, E. I., Martynov, M. Yu., Kostenko, E. V., Petrova, L. V., & Bobyreva, S. N. (2018). The efficacy of semax in the treatment of patients at different stages of ischaemic stroke. Journal of Neurology and Psychiatry named after S.S. Korsakov, 118(3), 61–68. https://doi.org/10.17116/jnevro20181183261-68
[16] Eremin, K. O., Kudrin, V. S., Saransaari, P., Oja, S. S., Grivennikov, I. A., Myasoedov, N. F., & Rayevsky, K. S. (2005). Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochemical Research, 30(12), 1493–1500. https://doi.org/10.1007/s11064-005-8826-8
[17] Eremin, K. O., Saransaari, P., Oja, S., & Raevskiĭ, K. S. (2004). Semax potentiates effects of D-amphetamine on the level of extracellular dopamine in the Sprague-Dawley rat striatum and on the locomotor activity of C57BL/6 mice. Experimental and Clinical Pharmacology, 67(2), 8–11. PMID: 15188751
[18] Filippenkov, I. B., Stavchansky, V. V., Denisova, A. E., Yuzhakov, V. V., Sevan’kaeva, L. E., Sudarkina, O. Yu., Dmitrieva, V. G., Gubsky, L. V., Myasoedov, N. F., Limborska, S. A., & Dergunova, L. V. (2020). Novel insights into the protective properties of ACTH(4-7)PGP (Semax) peptide at the transcriptome level following cerebral ischaemia-reperfusion in rats. Genes, 11(6), 681. https://doi.org/10.3390/genes11060681
[19] Dergunova, L. V., Dmitrieva, V. G., Filippenkov, I. B., Stavchansky, V. V., Denisova, A. E., Yuzhakov, V. V., Sevan’kaeva, L. E., Valieva, L. V., Sudarkina, O. Yu., Gubsky, L. V., Myasoedov, N. F., & Limborska, S. A. (2021). The peptide drug ACTH(4-7)PGP (Semax) suppresses mRNA transcripts encoding proinflammatory mediators induced by reversible ischemia of the rat brain. Molecular Biology, 55(3), 402–411. https://doi.org/10.31857/S0026898421010043
[20] Filippenkov, I. B., Glazova, N. Yu., Sebentsova, E. A., Stavchansky, V. V., Andreeva, L. A., Myasoedov, N. F., Levitskaya, N. G., Limborska, S. A., & Dergunova, L. V. (2024). Changes of transcriptomic activity in rat brain cells under the influence of synthetic adrenocorticotropic hormone-like peptides. Biochemistry (Moscow), 89(9), 1643–1656. https://doi.org/10.1134/S0006297924090104
[21] Dmitrieva, V. G., Povarova, O. V., Skvortsova, V. I., Limborska, S. A., Myasoedov, N. F., & Dergunova, L. V. (2010). Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischaemia. Cellular and Molecular Neurobiology, 30(1), 71–79. https://doi.org/10.1007/s10571-009-9432-0
Stavchansky, V. V., Yuzhakov, V. V., Botsina, A. Yu., Skvortsova, V. I., Bondurko, L. N., Tsyganova, M. G., Limborska, S. A., Myasoedov, N. F., & Dergunova, L. V. (2011). The effect of Semax and its C-end peptide PGP on the morphology and proliferative activity of rat brain cells during experimental ischemia: A pilot study. Journal of Molecular Neuroscience, 45(2), 177–185. https://doi.org/10.1007/s12031-010-9421-2
[23] Cherkasova, K. A., Lyapina, L. A., & Ashmarin, I. P. (2001). Comparative study of modulatory effects of Semax and primary proline-containing peptides on hemostatic reactions. Bulletin of Experimental Biology and Medicine, 132(1), 625–626. https://doi.org/10.1023/a:1012503606536
[24] Grigorjeva, M. E., & Lyapina, L. A. (2010). Anticoagulant and antiplatelet effects of semax under conditions of acute and chronic immobilisation stress. Bulletin of Experimental Biology and Medicine, 149(1), 44–46. https://doi.org/10.1007/s10517-010-0871-x
[25] Zhuikova, S. E., Smirnova, E. A., Bakaeva, Z. V., Samonina, G. E., & Ashmarin, I. P. (2000). Effect of Semax on homeostasis of gastric mucosa in albino rats. Bulletin of Experimental Biology and Medicine, 130(9), 871–873. PMID: 11177268
[26] Svishcheva, M. V., Mukhina, A. Yu., Medvedeva, O. A., Shevchenko, A. V., Bobyntsev, I. I., Kalutskii, P. V., Andreeva, L. A., & Myasoedov, N. F. (2020). Composition of colon microbiota in rats treated with ACTH(4-7)-PGP peptide (Semax) under conditions of restraint stress. Bulletin of Experimental Biology and Medicine, 169(3), 357–360. https://doi.org/10.1007/s10517-020-04886-7
[27] Bobyntsev, I. I., Shepeleva, O. M., Kryukov, A. A., Ivanov, A. V., & Belykh, A. E. (2015). The effect of peptide ACTH4-7-PGP on functional hepatocyte state in rats in acute and chronic foot-shock stress. Sechenov Physiological Journal, 101(2), 171–179. PMID: 26012109
[28] Samotrueva, M. A., Yasenyavskaya, A. L., Murtalieva, V. Kh., Bashkina, O. A., Myasoedov, N. F., Andreeva, L. A., & Karaulov, A. V. (2019). Experimental substantiation of application of Semax as a modulator of immune reaction on the model of „social” stress. Bulletin of Experimental Biology and Medicine, 166(6), 754–758. https://doi.org/10.1007/s10517-019-04434-y
[29] Umriukhin, P. E., Koplik, E. V., Grivennikov, I. A., Miasoedov, N. F., & Sudakov, K. V. (2001). Gene c-Fos expression in the brain of rats resistant and predisposed to emotional stress after intraperitoneal injection of the ACTH(4-10) analog — Semax. Journal of Higher Nervous Activity named after I. P. Pavlov, 51(2), 220–227. PMID: 11548604